5v7t - Revision history

OCA at 08:32, 30 September 2020

OCA — Wed, 30 Sep 2020 08:32:12 GMT

←Older revision		Revision as of 08:32, 30 September 2020
Line 1:		Line 1:

	==crystal structure of PARP14 bound to N-{4-[4-(diphenylmethoxy)piperidin-1-yl]butyl}[1,2,4]triazolo[4,3-b]pyridazin-6-amine inhibitor==		==crystal structure of PARP14 bound to N-{4-[4-(diphenylmethoxy)piperidin-1-yl]butyl}[1,2,4]triazolo[4,3-b]pyridazin-6-amine inhibitor==
-	<StructureSection load='5v7t' size='340' side='right' caption='[[5v7t]], [[Resolution\|resolution]] 2.30Å' scene=''>	+	<StructureSection load='5v7t' size='340' side='right'caption='[[5v7t]], [[Resolution\|resolution]] 2.30Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5v7t]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5V7T OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5V7T FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5v7t]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5V7T OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5V7T FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=91V:N-{4-[4-(DIPHENYLMETHOXY)PIPERIDIN-1-YL]BUTYL}[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-6-AMINE'>91V</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=91V:N-{4-[4-(DIPHENYLMETHOXY)PIPERIDIN-1-YL]BUTYL}[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-6-AMINE'>91V</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5v7w\|5v7w]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5v7w\|5v7w]]</td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PARP14, BAL2, KIAA1268 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/NAD(+)_ADP-ribosyltransferase NAD(+) ADP-ribosyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.4.2.30 2.4.2.30] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/NAD(+)_ADP-ribosyltransferase NAD(+) ADP-ribosyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.4.2.30 2.4.2.30] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5v7t FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5v7t OCA], [http://pdbe.org/5v7t PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5v7t RCSB], [http://www.ebi.ac.uk/pdbsum/5v7t PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5v7t ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5v7t FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5v7t OCA], [http://pdbe.org/5v7t PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5v7t RCSB], [http://www.ebi.ac.uk/pdbsum/5v7t PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5v7t ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
Line 20:		Line 21:
	</div>		</div>
	<div class="pdbe-citations 5v7t" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5v7t" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Poly(ADP-ribose) polymerase 3D structures\|Poly(ADP-ribose) polymerase 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Hirozane, M]]		[[Category: Hirozane, M]]
	[[Category: Saikatendu, k s]]		[[Category: Saikatendu, k s]]
	[[Category: Human parp14]]		[[Category: Human parp14]]
	[[Category: Transferase-transferase inhibitor complex]]		[[Category: Transferase-transferase inhibitor complex]]

OCA at 13:04, 4 May 2017

OCA — Thu, 04 May 2017 13:04:23 GMT

←Older revision		Revision as of 13:04, 4 May 2017
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5v7t is ~~ON HOLD until Paper~~ Publication	+	==crystal structure of PARP14 bound to N-{4-[4-(diphenylmethoxy)piperidin-1-yl]butyl}[1,2,4]triazolo[4,3-b]pyridazin-6-amine inhibitor==
		+	<StructureSection load='5v7t' size='340' side='right' caption='[[5v7t]], [[Resolution\|resolution]] 2.30Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5v7t]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5V7T OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5V7T FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=91V:N-{4-[4-(DIPHENYLMETHOXY)PIPERIDIN-1-YL]BUTYL}[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-6-AMINE'>91V</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5v7w\|5v7w]]</td></tr>
		+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/NAD(+)_ADP-ribosyltransferase NAD(+) ADP-ribosyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.4.2.30 2.4.2.30] </span></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5v7t FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5v7t OCA], [http://pdbe.org/5v7t PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5v7t RCSB], [http://www.ebi.ac.uk/pdbsum/5v7t PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5v7t ProSAT]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/PAR14_HUMAN PAR14_HUMAN]] Enhances STAT6-dependent transcription (By similarity). Has ADP-ribosyltransferase activity.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Poly(ADP-ribose) polymerases (PARPs) use nicotinamide adenine dinucleotide (NAD+) as a co-substrate to transfer ADP-ribose when it releases nicotinamide as the metabolized product. Enzymes of the PARP family play key roles in detecting and repairing DNA, modifying chromatin, regulating transcription, controlling energy metabolism, and inducing cell death. PARP14, the original member of the PARP family, has been reported to be associated with the development of inflammatory diseases and various cancer types, making it a potential therapeutic target. In this study, we purified the macrodomain-containing PARP14 enzyme and established an assay for detecting the auto-ribosylation activity of PARP14 using RapidFire high-throughput mass spectrometry and immunoradiometric assay using [3H]NAD+. Subsequently, we performed high-throughput screening using the assays and identified small-molecule hit compounds, which showed NAD+-competitive and PARP14-selective inhibitory activities. Co-crystal structures of PARP14 with certain hit compounds revealed that the inhibitors bind to the NAD+-binding site. Finally, we confirmed that the hit compounds interacted with intracellular PARP14 by a cell-based protein stabilization assay. Thus, we successfully identified primary candidate compounds for further investigation.

-	~~Authors~~:	+	Identification of PARP14 inhibitors using novel methods for detecting auto-ribosylation.,Yoneyama-Hirozane M, Matsumoto SI, Toyoda Y, Saikatendu KS, Zama Y, Yonemori K, Oonishi M, Ishii T, Kawamoto T Biochem Biophys Res Commun. 2017 May 6;486(3):626-631. doi:, 10.1016/j.bbrc.2017.03.052. Epub 2017 Mar 14. PMID:28315326<ref>PMID:28315326</ref>

-	~~Description~~:	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
		+	<div class="pdbe-citations 5v7t" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Hirozane, M]]
		+	[[Category: Saikatendu, k s]]
		+	[[Category: Human parp14]]
		+	[[Category: Transferase-transferase inhibitor complex]]

OCA at 09:42, 12 April 2017

OCA — Wed, 12 Apr 2017 09:42:30 GMT

←Older revision		Revision as of 09:42, 12 April 2017
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5v7t is ON HOLD	+	The entry 5v7t is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "5v7t" [edit=sysop:move=sysop]

OCA — Wed, 05 Apr 2017 11:42:20 GMT

Protected "5v7t" [edit=sysop:move=sysop]

←Older revision

Revision as of 11:42, 5 April 2017

OCA: New page: '''Unreleased structure''' The entry 5v7t is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 05 Apr 2017 11:42:19 GMT

New page: '''Unreleased structure''' The entry 5v7t is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 5v7t is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]